By Daniella Parra
Octave announced new data at the Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting 2023, supporting the company’s solution for multiple sclerosis.
Researchers assayed 747 patient samples with Octave’s Multiple Sclerosis Disease Activity (MSDA) test, finding eight clusters with distinct protein signatures that were further evaluated relative to key clinical variables, it said in a statement.
“The robustness of learned protein signatures across datasets is reassuring evidence for the clinical utility of this methodology,” said John F. Foley, MD, Founder of Rocky Mountain MS Clinic.“These clusters will serve as the kernel of patient profiles for further exploration in the clinical utility of variables of interest, including disease activity score distributions in clinically stable versus active patients, the impact of duration of disease-modifying therapy (DMT), and for comparisons of DMTs with diverse mechanisms of action.”
Contact:
Editor@Executives-edge.com
